• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Notable Labs Launches by Acquiring Rights to Volasertib – Will Use Data, AI to Fast-Track Cancer Treatment

by Fred Pennic 11/11/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Thomas Bock, M.D., Chief Executive Officer of Notable

What You Should Know:

– Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.

– Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development in this patient population.

– Notable’s proprietary platform was built upon deep expertise across therapeutics, diagnostics, software, engineering, machine learning and automation. It quickly determines the response profile of individual patients prior to their cancer treatment, allowing for selective enrollment of predicted clinical responders into clinical trials.

License Agreement

Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications.  Oncoheroes will retain the license for the development and commercialization of volasertib in other pediatric indications. Financial terms of this deal are not disclosed.

Predictive Precision Medicines

Notable represents a new way to develop therapies – with data and analytics behind it – and the company’s data is supported by a recent Stanford study showing a 92% accuracy in predicting patient response. Traditional precision medicine uses biomarkers and genetic screening to improve development success. It works but in the big picture, it has decreased failure only moderately – from 96.6% to 95%. Notable’s platform was built upon the team’s deep expertise in therapeutics, diagnostics, software, engineering, machine learning and automation. 

“Volasertib represents an exciting milestone towards fulfilling Notable’s mission to deliver life-changing therapies precisely to those who will benefit, and leads the way in a new era of predictive precision medicine,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “We targeted and licensed volasertib because of its compelling performance on our Predictive Precision Medicine Platform and as an important addition to our growing clinical pipeline. We plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers, selectively enrolling patients who are predicted to respond.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: AI, Artificial Intelligence, cancer, Cancer Diagnostics, Notable, Precision Medicine, Precision Medicine Oncology

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

How to Build Hybrid Care Models Around Remote Patient Monitoring

How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Podimetrics CMO Talks Supporting Patients Living with SDoH Challenges

Podimetrics CMO Talks Supporting Patients Living with SDoH Challenges

Recent Digital Health Partnerships

Roundups: 15 Recent Digital Health Strategic Partnerships

Recent Digital Health Executive Hires & Board Appointments

Digital Health Executive Hires: Practice Better Appoints CEO, HHAeXchange, Intelerad, Tegria, Others

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

How AI Can Eliminate Surprise Bills, Improve Payment Integrity

AI Can Eliminate Surprise Bills, Improve Payment Integrity

Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |